Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Blood (2024) 144 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2024-207591

Published: 2024

Journal Articles

Incidence, Risk Factors, Microbiology and Outcomes of Bloodstream Infection during Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation

Ling Pan, Li Jia, Xiaomeng Feng, Erlie Jiang, Sizhou Feng

Blood (2024) 144 (Supplement 1): 7287.

https://doi.org/10.1182/blood-2024-204385

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Xiao-shuai Zhang, Bingcheng Liu, Jian Huang, Xin Du, Yanli Zhang, Na Xu, Xiaoli Liu, Li Weiming, Hai Lin, Huanling Zhu, Yunfan Yang, Ling Pan, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2023-185473

Published: 2023

Journal Articles

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

Zefeng Xu, Ling Pan, Zhenya Hong, Qingsong Yin, Xuelan Zuo, Qin Wen, Fan Yu, Chunkang Chang, Wei Ling, Dong Wang, Dawei Ding, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2023-178956

Published: 2023

Journal Articles

Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study

Hong Chang, Ling Pan, Yongqian Jia, Bing Xiang, Xiaoou Huang, Yong Guo, Meng Li, Hongyun Xing, Fang Xu, Ying Yuan, Ying Lian, Lihua Yang, Ting Niu

Blood (2023) 142 (Supplement 1): 5631.

https://doi.org/10.1182/blood-2023-185469

Published: 2023

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 815–817.

https://doi.org/10.1182/blood-2022-166855

Published: 2022

Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 9620–9623.

https://doi.org/10.1182/blood-2022-166431

Published: 2022

Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Blood (2022) 140 (Supplement 1): 9637–9639.

https://doi.org/10.1182/blood-2022-168703

Published: 2022

Journal Articles

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136236

Published: 2020

Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137742

Published: 2020

Journal Articles

Onset of Regulatory B Cells Occurs at Initial Stage of B Cell Dysfunction in Multiple Myeloma

Zhongqing Zou, Tingting Guo, Jian Cui, Li Zhang, Ling Pan

Blood (2019) 134 (Supplement_1): 1780.

https://doi.org/10.1182/blood-2019-128703

Published: 2019

Journal Articles

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

Yunfan Yang, MD, Zhongqing Zou, MD, Ting Liu, MD PhD, Yongqian Jia, PhD, Ting Niu, MD PhD, Huanling Zhu, MD, Yu Wu, MD, Yuping Gong, MD, Hong Chang, MD, Jie Ji, MD, Jian Li, MD, Ling Pan

Blood (2019) 134 (Supplement_1): 5384.

https://doi.org/10.1182/blood-2019-128553

Published: 2019

Journal Articles

Retrospective Treatment Analysis of a Series of 104 Patients with Adult Onset Hemophagocytic Lymphohistiocytosis in a Single Institution of China

Blood (2016) 128 (22): 4882.

https://doi.org/10.1182/blood.V128.22.4882.4882

Published: 2016

Journal Articles

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Lung-Ji Chang, PhD, Lujia Dong, MD, Jun Zhu, MD, Zhitao Ying, MD, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Yu-Qin Song, MD, Xiao-Pei Wang, MD, Yong-Qian Jia, MD, Ting Niu, MD PhD, Ting Liu, MDPhD, Ling Pan, MD, Zhuo-Gang Liu, MD, Tong Li, MD, Ying-Chun Li, MD, Kun Yao, MD, Xiaoyan Ke, MD PhD, Hongmei Jing, MD, Fang Bao, MD

Blood (2015) 126 (23): 264.

https://doi.org/10.1182/blood.V126.23.264.264

Published: 2015

Journal Articles

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, MD, Peng Wei, PhD, Shifang Yang, PhD, Xiangjun Zheng, Lugui Qiu, MD, Jian Hou, MD PhD, Xuejun Zhang, MD, Zhao Wang, Xiaoyan Ke, MD PhD, Ling Pan, MDPhD, Hongyan Pang, PhD

Blood (2014) 124 (21): 3478.

https://doi.org/10.1182/blood.V124.21.3478.3478

Published: 2014

Journal Articles

Decitabine Combined With Chemotherapy For The Treatment Of Refractory Acute Myeloid Leukemia: a Pilot Phase 1 Clinical Study

Ling Pan, MD, PhD, Meng Chen, Yongqian Jia, MD, PhD, Xu Cui, MD, Ting Niu, MD, PhD, Hong Chang, MD, PhD, Hongbing Ma, MD, Jianjun Li, MD, Yuping Gong, MD, PhD, Xinchuan Chen, MD, Ting Liu, MD, PhD

Blood (2013) 122 (21): 5001.

https://doi.org/10.1182/blood.V122.21.5001.5001

Published: 2013

Journal Articles

This Is a Title In Title Case: Safety and Efficacy of Intravenous 4.5g/m2 Methotrexate over 90 Minutes for Hematological Malignancy with Cerebral Involvement

Ling Pan, MD, PhD, Meng Chen, Li Zhang, MD, PhD, Yongqian Jia, MD, PhD, Ting Niu, MD, PhD

Blood (2013) 122 (21): 5566.

https://doi.org/10.1182/blood.V122.21.5566.5566

Published: 2013

Journal Articles

Recombinant Circularly Permuted TRAIL (CPT) for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial

Wenming Chen, MD, Lugui Qiu, MD, Jian Hou, MD, PhD, Yaozhong Zhao, Ling Pan, Shifang Yang, PhD, Yun Leng, Hao Xi, Xuejun Zhang, Junsheng Cui, Na Wei

Blood (2012) 120 (21): 78.

https://doi.org/10.1182/blood.V120.21.78.78

Published: 2012

NARROW

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Incidence, Risk Factors, Microbiology and Outcomes of Bloodstream Infection during Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Onset of Regulatory B Cells Occurs at Initial Stage of B Cell Dysfunction in Multiple Myeloma

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

Retrospective Treatment Analysis of a Series of 104 Patients with Adult Onset Hemophagocytic Lymphohistiocytosis in a Single Institution of China

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

Decitabine Combined With Chemotherapy For The Treatment Of Refractory Acute Myeloid Leukemia: a Pilot Phase 1 Clinical Study

This Is a Title In Title Case: Safety and Efficacy of Intravenous 4.5g/m2 Methotrexate over 90 Minutes for Hematological Malignancy with Cerebral Involvement

Recombinant Circularly Permuted TRAIL (CPT) for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only